Physician profile
Ragisha Gopalakrishnan
NPI 1538502620
$15,664.52
in general payments reported to CMS, 2019-2025
54 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.00 · 2021: $435 · 2022: $4,548 · 2023: $9,077 · 2024: $1,490 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,418 · Food and Beverage: $4,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,417.50 |
| Food and Beverage | $4,251.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,877.30 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,746.72 | 2021-2024 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $2,706.66 | 2021-2024 | Trodelvy |
| Pfizer INC. | $1,426.49 | 2023-2024 | |
| Celgene Corporation | $813.88 | 2021-2024 | Reblozyl |
| Daiichi Sankyo INC. | $563.79 | 2022-2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $526.35 | 2022-2024 | |
| Janssen Biotech, INC. | $479.01 | 2021-2024 | Erleada, Darzalex, Rybrevant |
| Genmab U.S., INC. | $290.10 | 2023-2024 | Epkinly |
| Merck Sharp & Dohme LLC | $261.60 | 2021-2024 | Keytruda, Lynparza |
| Seagen INC. | $233.58 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Genzyme Corporation | $216.25 | 2021-2024 | |
| Abbvie INC. | $181.98 | 2021-2025 | |
| Sirtex Medical INC | $165.18 | 2021 | |
| Tempus Ai, INC | $156.13 | 2024 | Xt Cdx |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $146.43 | 2022-2025 | Xospata, Padcev |
| Incyte Corporation | $140.77 | 2021-2024 | Jakafi |
| Mirati Therapeutics, INC. | $133.99 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $132.92 | 2021-2023 | Jemperli, Zejula |
| Emd Serono, INC. | $126.85 | 2022-2024 | Bavencio |
| Genentech USA, INC. | $119.89 | 2021-2024 | Lunsumio, Polivy, Rozlytrek |
| Servier Pharmaceuticals LLC | $109.19 | 2022-2023 | |
| Array Biopharma INC | $98.03 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
| Morphosys, US INC. | $85.07 | 2022-2023 | Monjuvi |
| Puma Biotechnology, INC. | $74.18 | 2023 | |
| Stemline Therapeutics INC. | $71.55 | 2023-2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $63.11 | 2022-2023 | Clonoseq |
| Amgen INC. | $60.78 | 2022 | |
| Deciphera Pharmaceuticals INC. | $45.08 | 2023-2024 | Qinlock |
| Exelixis INC. | $44.42 | 2022-2023 | Cabometyx |
| Springworks Therapeutics, INC. | $42.68 | 2024 | Ogsiveo |
| Pharmacyclics LLC, An Abbvie Company | $39.80 | 2023 | Epkinly, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $36.17 | 2023-2024 | Fruzaqla, Iclusig |
| Alexion Pharmaceuticals, INC. | $34.64 | 2024 | Ultomiris |
| Adc Therapeutics America, INC. | $33.71 | 2022 | |
| Aveo Pharmaceuticals, INC. | $32.24 | 2023 | Fotivda |
| Blueprint Medicines Corporation | $31.60 | 2023 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $30.61 | 2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $28.02 | 2022 | |
| Beigene USA, INC. | $26.90 | 2021-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $25.30 | 2023 | |
| Myovant Sciences INC. | $24.00 | 2022 | |
| Epizyme, INC. | $23.89 | 2022 | |
| Karyopharm Therapeutics INC. | $21.39 | 2024 | Xpovio |
| Taiho Oncology, INC. | $20.46 | 2023 | |
| Kite Pharma, INC. | $20.23 | 2023 | Yescarta |
| G1 Therapeutics, INC. | $20.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.55 | 2024 | Opdivo |
| Pharmacosmos Therapeutics INC. | $18.27 | 2024 | Cosela |
| Lilly USA, LLC | $13.47 | 2024 | Jaypirca, Retevmo, Verzenio |
| Tosoh Bioscience, INC. | $13.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ragisha Gopalakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.